Memory B-cell depletion is a feature of HIV-2 infection even in the absence of detectable viremia

AIDS

Volumn 26, Issue 13, 2012, Pages 1607-1617

  Tendeiro, Rita ^a   Fernandes, Sofia ^a   Foxall, Russell B ^a   Marcelino, José M ^a,b   Taveira, Nuno ^a,c   Soares, Rui S ^a   Baptista, António P ^a   Cavaleiro, Rita ^a   Gomes, Perpétua ^b,c,d   Victorino, Rui M M ^a,e   Sousa, Ana E ^a  

^a UNIVERSITY OF LISBON   (Portugal)

^b INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^c INSTITUTO SUPERIOR DE CIÊNCIAS DA SAÚDE EGAS MONIZ   (Portugal)

^d HOSPITAL EGAS MONIZ   (Portugal)

^e HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

AIDS; B cell activating factor; B cells; HIV 2; immune activation; memory B cells

Indexed keywords

ANTIRETROVIRUS AGENT; B CELL ACTIVATING FACTOR; BETA 2 MICROGLOBULIN; CD27 ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN D; INTERLEUKIN 7;

ADULT; AGED; ANTIBODY SPECIFICITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; IMMUNOGLOBULIN BLOOD LEVEL; LYMPHOCYTE SUBPOPULATION; MALE; MEMORY CELL; PRIORITY JOURNAL; RANK SUM TEST; SEROLOGY; T LYMPHOCYTE ACTIVATION; VIREMIA; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTE SUBSETS; B-LYMPHOCYTES; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HIV-1; HIV-2; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; RNA, VIRAL; VIRAL LOAD; VIREMIA;

EID: 84865461543     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283568849     Document Type: Article

References (54)

1. Lane HC, Masur H, Edgar LC, Whalen G, Rook AH, Fauci AS. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med 1983; 309:453-458. (Pubitemid 13041485)
2. De Milito A, Morch C, Sonnerborg A, Chiodi F. Loss of memory (CD27) B lymphocytes in HIV-1 infection. AIDS 2001; 15:957-964. (Pubitemid 32476662)
3. Moir S, Malaspina A, Ogwaro KM, Donoghue ET, Hallahan CW, Ehler LA, et al. HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc Natl Acad Sci USA 2001; 98:10362-10367. (Pubitemid 32803025)
4. van Grevenynghe J, Cubas RA, Noto A, DaFonseca S, He Z, Peretz Y, et al. Loss of memory B cells during chronic HIV infection is driven by Foxo3a-and TRAIL-mediated apoptosis. J Clin Invest 2011; 121:3877-3888.
5. De Milito A, Nilsson A, Titanji K, Thorstensson R, Reizenstein E, Narita M, et al. Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood 2004; 103:2180-2186. (Pubitemid 38326236)
6. Titanji K, Chiodi F, Bellocco R, Schepis D, Osorio L, Tassandin C, et al. Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions. AIDS 2005; 19:1947-1955. (Pubitemid 41669018)
7. Rieckmann P, Poli G, Fox CH, Kehrl JH, Fauci AS. Recombinant gp120 specifically enhances tumor necrosis factor-alpha production and Ig secretion in B lymphocytes from HIV-infected individuals but not from seronegative donors. J Immunol 1991; 147:2922-2927.
8. He B, Qiao X, Klasse PJ, Chiu A, Chadburn A, Knowles DM, et al. HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J Immunol 2006; 176:3931-3941. (Pubitemid 44264370)
9. Qiao X, He B, Chiu A, Knowles DM, Chadburn A, Cerutti A. Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. Nat Immunol 2006; 7:302-310.
10. Swingler S, Zhou J, Swingler C, Dauphin A, Greenough T, Jolicoeur P, Stevenson M. Evidence for a pathogenic determinant in HIV-1 Nef involved in B cell dysfunction in HIV/AIDS. Cell Host Microbe 2008; 4:63-76. (Pubitemid 351958115)
11. Popper SJ, Sarr AD, Travers KU, Gueye-Ndiaye A, Mboup S, Essex ME, Kanki PJ. Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. J Infect Dis 1999; 180:1116-1121. (Pubitemid 30070194)
12. Sousa AE, Carneiro J, Meier-Schellersheim M, Grossman Z, Victorino RM. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol 2002; 169:3400-3406. (Pubitemid 35013190)
13. Kanki PJ, Travers KU, Mboup S, Hsieh CC, Marlink RG, Gueye NA, et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet 1994; 343:943-946. (Pubitemid 24117229)
14. O'Donovan D, Ariyoshi K, Milligan P, Ota M, Yamuah L, Sarge-Njie R, Whittle H. Maternal plasma viral RNA levels determine marked differences in mother-to-child transmission rates of HIV-1 and HIV-2 in The Gambia. MRC/Gambia Government/University College London Medical School working group on mother-child transmission of HIV. AIDS 2000; 14:441-448. (Pubitemid 30182442)
15. Valadas E, Franca L, Sousa S, Antunes F. 20 years of HIV-2 infection in Portugal: trends and changes in epidemiology. Clin Infect Dis 2009; 48:1166-1167.
16. Carvalho A, Valadas E, Franca L, Carvalho C, Aleixo M, Mendez J, et al. Population mobility and the changing epidemics of HIV-2 in Portugal. HIV Med 2011.
17. Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994; 265:1587-1590. (Pubitemid 24308975)
18. van der Loeff MF, Larke N, Kaye S, Berry N, Ariyoshi K, Alabi A, et al. Undetectable plasma viral load predicts normal survival in HIV-2-infected people in a West African village. Retrovirology 2010; 7:46.
19. Poulsen AG, Aaby P, Larsen O, Jensen H, Naucler A, Lisse IM, et al. 9-year HIV-2-associated mortality in an urban community in Bissau, west Africa. Lancet 1997; 349:911-914. (Pubitemid 27139820)
20. Drylewicz J, Matheron S, Lazaro E, Damond F, Bonnet F, Simon F, et al.Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France. AIDS 2008; 22:457-468. (Pubitemid 351317287)
21. Grossman Z, Meier-Schellersheim M, Sousa AE, Victorino RM, Paul WE. CD4R T-cell depletion in HIV infection: are we closer to understanding the cause?. Nat Med 2002; 8:319-323. (Pubitemid 34407019)
22. Kestens L, Brattegaard K, Adjorlolo G, Ekpini E, Sibailly T, Diallo K, et al. Immunological comparison of HIV-1-, HIV-2-and dually-reactive women delivering in Abidjan, Cote d'Ivoire. AIDS 1992; 6:803-807.
23. Marcelino JM, Nilsson C, Barroso H, Gomes P, Borrego P, Maltez F, et al. Envelope-specific antibody response in HIV-2 infection: C2V3C3-specific IgG response is associated with disease progression. AIDS 2008; 22:2257-2265.
24. Brun-Vezinet F, Rey MA, Katlama C, Girard PM, Roulot D, Yeni P, et al. Lymphadenopathy-associated virus type 2 in AIDS and AIDS-related complex. Clinical and virological features in four patients. Lancet 1987; 1:128-132. (Pubitemid 17015823)
25. Bjorling E, Scarlatti G, von Gegerfelt A, Albert J, Biberfeld G, Chiodi F, et al. Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection. Virology 1993; 193:528-530.
26. Ozkaya Sahin G, Holmgren B, da Silva Z, Nielsen J, Nowroozalizadeh S, Esbjornsson J, et al. Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1. J Virol 2012; 86:961-971.
27. de Silva TI, Aasa-Chapman M, Cotten M, Hue S, Robinson J, Bibollet-Ruche F, et al. Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes. J Virol 2012; 86:930-946.
28. Kong R, Li H, Bibollet-Ruche F, Decker JM, Zheng NN, Gottlieb GS, et al. Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection. J Virol 2012; 86:947-960.
29. Marcelino JM, Barroso H, Goncalves F, Silva SM, Novo C, Gomes P, et al. Use of a new dual-antigen enzyme-linked immunosorbent assay to detect and characterize the human antibody response to the human immunodeficiency virus type 2 envelope gp125 and gp36 glycoproteins. J Clin Microbiol 2006; 44:607-611. (Pubitemid 43222261)
30. Barroso H, Borrego P, Bartolo I,Marcelino JM, Familia C, Quintas A, Taveira N. Evolutionary and structural features of the C2, V3 and C3envelope regions underlying the differences in HIV-1 and HIV-2 biology and infection. PLoS One 2011; 6:e14548.
31. Soares RS, Tendeiro R, Foxall RB, Baptista AP, Cavaleiro R, Gomes P, et al. Cell-associated viral burden provides evidence of ongoing viral replication in aviremic HIV-2-infected patients. J Virol 2011; 85:2429-2438.
32. Popper SJ, Sarr AD, Gueye-Ndiaye A, Mboup S, Essex ME, Kanki PJ. Low plasma human immunodeficiency virus type 2 viral load is independent of proviral load: low virus production in vivo. J Virol 2000; 74:1554-1557. (Pubitemid 30044108)
33. Soares R, Foxall R, Albuquerque A, Cortesao C, Garcia M, Victorino RM, Sousa AE. Increased frequency of circulating CCR5R CD4R T cells in human immunodeficiency virus type 2 infection. J Virol 2006; 80:12425-12429. (Pubitemid 44904396)
34. Cavaleiro R, Baptista AP, Soares RS, Tendeiro R, Foxall RB, Gomes P, et al. Major depletion of plasmacytoid dendritic cells in HIV-2 infection, an attenuated form of HIV disease. PLoS Pathog 2009; 5:e1000667.
35. Moir S, Fauci AS. Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease. J Allergy Clin Immunol 2008; 122:12-19; quiz 20-11.
36. Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2002; 2:465-475. (Pubitemid 37328738)
37. Fontaine J, Chagnon-Choquet J, Valcke HS, Poudrier J, Roger M. High expression levels of B lymphocyte stimulator (BLyS) by dendritic cells correlate with HIV-related B-cell disease progression in humans. Blood 2011; 117:145-155.
38. Rodriguez B, Valdez H, Freimuth W, Butler T, Asaad R, Lederman MM. Plasma levels of B-lymphocyte stimulator increase with HIV disease progression. AIDS 2003; 17:1983-1985. (Pubitemid 37070285)
39. Albuquerque AS, Cortesao CS, Foxall RB, Soares RS, Victorino RM, Sousa AE. Rate of increase in circulating IL-7 and loss of IL-7Ralpha expression differ in HIV-1 and HIV-2 infections: two lymphopenic diseases with similar hyperimmune activation but distinct outcomes. J Immunol 2007; 178:3252-3259. (Pubitemid 46333208)
40. Foxall RB, Soares RS, Albuquerque AS, Cortesao CS, Victorino RM, Sousa AE. Increased frequency of CD25dimCD4R T-cells in HIV-2 infection, a naturally occurring attenuated form of HIV-1. Clin Immunol 2008; 127:158-167.
41. Sousa AE, Chaves AF, Loureiro A, Victorino RM.Comparison of the frequency of interleukin (IL)-2-, interferon-gamma-, and IL-4-producing T cells in 2 diseases, human immunodeficiency virus types 1 and 2, with distinct clinical outcomes. J Infect Dis 2001; 184:552-559. (Pubitemid 32783545)
42. Klein U, Kuppers R, Rajewsky K. Human IgMRIgDR B cells, the major B cell subset in the peripheral blood, express V kappa genes with no or little somatic mutation throughout life. Eur J Immunol 1993; 23:3272-3277. (Pubitemid 23353778)
43. Klein U, Kuppers R, Rajewsky K. Variable region gene analysis of B cell subsets derived from a 4-year-old child: somatically mutated memory B cells accumulate in the peripheral blood already at young age. J Exp Med 1994; 180:1383-1393. (Pubitemid 24289612)
44. Zeng M, Smith AJ, Wietgrefe SW, Southern PJ, Schacker TW, Reilly CS, et al. Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J Clin Invest 2011; 121:998-1008.
45. Rademakers LH, Schuurman HJ, de Frankrijker JF, Van Ooyen A. Cellular composition of germinal centers in lymph nodes after HIV-1 infection: evidence for an inadequate support of germinal center B lymphocytes by follicular dendritic cells. Clin Immunol Immunopathol 1992; 62:148-159.
46. Pantaleo G, Cohen OJ, Schacker T, Vaccarezza M, Graziosi C, Rizzardi GP, et al. Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: implications for antiviral therapy. Nat Med 1998; 4:341-345. (Pubitemid 28144095)
47. Schramm B, Penn ML, Palacios EH, Grant RM, Kirchhoff F, Goldsmith MA. Cytopathicity of human immunodeficiency virus type 2 (HIV-2) in human lymphoid tissue is coreceptor dependent and comparable to that of HIV-1. J Virol 2000; 74:9594-9600.
48. Chiara M, Rony Z, Homa M, Bhanumati V, Ladomirska J, Manzi M, et al. Characteristics, immunological response and treatment outcomes of HIV-2 compared with HIV-1 & dual infections (HIV 1/2) in Mumbai. Indian J Med Res 2010; 132:683-689.
49. van der Ende ME, Prins JM, Brinkman K, Keuter M, Veenstra J, Danner SA, et al. Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients. AIDS 2003; 17 (Suppl 3):S55-61. (Pubitemid 36951670)
50. Moir S, Buckner CM, Ho J, Wang W, Chen J, Waldner AJ, et al. B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood 2010; 116:5571-5579.
51. Buzon MJ, Codoner FM, Frost SD, Pou C, Puertas MC, Massanella M, et al. Deep molecular characterization of HIV-1 dynamics under suppressive HAART. PLoS Pathog 2011; 7:e1002314.
52. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011; 62:141-155.
53. Malaspina A, Moir S, Ho J, Wang W, Howell ML, O'Shea MA, et al. Appearance of immature/transitional B cells in HIVinfected individuals with advanced disease: correlation with increased IL-7. Proc Natl Acad Sci US A 2006; 103:2262-2267. (Pubitemid 43271658)
54. Moir S, Malaspina A, Pickeral OK, Donoghue ET, Vasquez J, Miller NJ, et al. Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily. J Exp Med 2004; 200:587-599. (Pubitemid 39258308)